Ultragenyx Pharmaceutical Inc. (RARE) ownership: insiders 2% · institutions 101% · index and ETF funds 8% (13F 2026-03-31). Insider activity, 90 days: 6 sales, 0 open-market buys. 4 recent congressional STOCK Act disclosures. SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| Vanguard | 10324989.00 | $216.31M | 10.5% | 2026-03-31 |
| BlackRock | 7299598.00 | $152.93M | 7.4% | 2026-03-31 |
| State Street | 5021441.00 | $105.20M | 5.1% | 2026-03-31 |
| AQR Capital Management | 4578024.00 | $95.91M | 4.6% | 2026-03-31 |
| RTW Investments, LP | 3648795.00 | $76.44M | 3.7% | 2026-03-31 |
| Sands Capital Management, LLC | 3214533.00 | $67.34M | 3.3% | 2026-03-31 |
| Sofinnova Investments, Inc. | 3145888.00 | $65.91M | 3.2% | 2026-03-31 |
| Baker BROS. Advisors LP | 2772692.00 | $63.77M | 2.8% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-07-01 | |
| Sell | null | 2026-06-15 | |
| Sell | null | 2026-06-15 | |
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-05-18 | |
| Sell | null | 2026-05-14 |
Back to RARE overview · RARE earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.